THSC-01 is under clinical development by Jiangsu Topcel-KH Pharmaceutical and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the THSC-01 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
THSC-01 is under development for the treatment of complex perianal fistulas in perianal Crohn's disease (CD) and radiation-induced rectal injury. The therapeutic candidate comprises allogeneic umbilical cord-derived mesenchymal stem cells. It is administered through perilesional route as injection in the form of a suspension.
Jiangsu Topcel-KH Pharmaceutical overview
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. is a pharmaceutical and healthcare company which is involved in research and development of medicianal drugs. The company is headquartered in Lianyungang, Jiangsu, China.
For a complete picture of THSC-01’s drug-specific PTSR and LoA scores, buy the report here.